G1 Therapeutics, Inc.
NasdaqGS:GTHX Voorraadrapport
Marktkapitalisatie: US$378.2m
This company has been acquired The company may no longer be operating, as it has been acquired. Find out why through their latest events.
See Latest Events G1 Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6 G1 Therapeutics is de winst gegroeid met een gemiddeld jaarlijks percentage van 9.2%, terwijl de Biotechs industrie de winst jaarlijks groeide met 19.3%. De inkomsten zijn gegroeid met een gemiddelde van 38.8% per jaar.
Belangrijke informatie
14.4%
Groei van de winst per aandeel
Biotechs Groei van de industrie 17.0% Inkomstengroei 38.8% Rendement op eigen vermogen -182.1% Nettomarge -76.9% Laatste winstupdate 30 Jun 2024
Recente prestatie-updates uit het verleden
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 09
G1 Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 26
First quarter 2024 earnings: EPS in line with expectations, revenues disappoint May 02
G1 Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024 Apr 19
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 01
G1 Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 16
Toon alle updates G1 Therapeutics, Inc.(NasdaqGS:GTHX) dropped from NASDAQ Composite Index
New minor risk - Shareholder dilution Aug 23
Consensus EPS estimates upgraded to US$0.39 loss Aug 15
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 09 Pharmacosmos Therapeutics Inc. entered into a definitive merger agreement to acquire G1 Therapeutics, Inc. (NasdaqGS:GTHX) for approximately $390 million.
New major risk - Share price stability Aug 08
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise Jul 26
G1 Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 26
Price target decreased by 10.0% to US$7.50 Jun 24 G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty Jun 24
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why Jun 07
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues May 28
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting May 24
CEO, President & Director recently sold US$178k worth of stock May 17
Consensus estimates of losses per share improve by 18% May 08
G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year May 04
First quarter 2024 earnings: EPS in line with expectations, revenues disappoint May 02
G1 Therapeutics, Inc., Annual General Meeting, Jun 13, 2024 Apr 28
G1 Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024 Apr 19
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape Mar 22
Forecast breakeven date pushed back to 2026 Mar 08
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 01
G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024 Mar 01
Consensus estimates of losses per share improve by 22% Feb 29
Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge Feb 27
G1 Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 16
Chief Medical Officer notifies of intention to sell stock Feb 14
Price target decreased by 12% to US$8.33 Feb 14
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee Feb 13
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet? Feb 06
G1 Therapeutics, Inc. Announces Updates, Including Encouraging Preliminary Overall Survival Data from the Ongoing Phase 2 Trial of Trilaciclib in Combination with the ADC Sacituzumab Govitecan in Patients with TNBC Jan 08
CEO, President & Director recently sold US$108k worth of stock Jan 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry Jan 04
Chief Medical Officer notifies of intention to sell stock Dec 13
New major risk - Share price stability Dec 07
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 03 G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023 Nov 02
New minor risk - Share price stability Oct 20 G1 Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023
G1 Therapeutics, Inc. Announces Resignation of Mark A. Velleca from the Board of Directors, Effective as of September 30, 2023 Sep 22
Consensus EPS estimates upgraded to US$0.96 loss Aug 18
Price target decreased by 21% to US$8.80 Aug 17
New minor risk - Market cap size Aug 15
New minor risk - Profitability Aug 11
No longer forecast to breakeven Aug 10
Consensus estimates of losses per share improve by 29% Aug 09
G1 Therapeutics, Inc. Provides Financial Guidance for the Full Year 2023 Aug 03
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 02
G1 Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues Jun 08
G1 Therapeutics Announces Appointment of Monica Thomas as Chief Compliance Officer May 24
Forecast to breakeven in 2025 May 12
G1 Therapeutics, Inc. Presents New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate May 11
Consensus revenue estimates increase by 26% May 10
New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX) May 08
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 05
G1 Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2023 May 04
Consensus EPS estimates upgraded to US$2.01 loss, revenue downgraded Mar 09
Full year 2022 earnings: EPS exceeds analyst expectations Mar 03
Consensus EPS estimates upgraded to US$2.19 loss, revenue downgraded Mar 02
G1 Therapeutics, Inc. Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with Folfoxiri + Bevacizumab for Metastatic Colorectal Cancer (CRC) (Preserve 1) Feb 15
Price target decreased by 45% to US$16.40 Feb 13
CEO, President & Director recently sold US$219k worth of stock Jan 10
G1 Therapeutics, Inc. Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib Jan 10
CEO, President & Director notifies of intention to sell stock Jan 08
G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (Pfs) Data Expected in Mid-2023 Jan 05
G1 Therapeutics, Inc. Announces Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Dec 09 G1 Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.05 million. Nov 18
Price target decreased to US$32.86 Nov 17
The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts Nov 04
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 03
G1 Therapeutics, Inc. Announces Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (Adc) Nov 03
G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer Oct 27
Senior Advisor & Director exercised options and sold US$170k worth of stock Oct 21
G1 Therapeutics: Catalysts Stacking Oct 20
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (Tnbc) Oct 11
G1 Therapeutics: Building A Franchise Sep 29
Senior Advisor & Director exercised options and sold US$262k worth of stock Sep 23
Insider notifies of intention to sell stock Sep 17
Senior Advisor & Director exercised options and sold US$980k worth of stock Aug 19
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 04
Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Aug 04
G1 Therapeutics Q2 2022 Earnings Preview Aug 02
Consensus forecasts updated Jul 30
G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors Jul 26
G1 Therapeutics: Take Advantage Of The November Data Jul 22
G1 Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 21
Hoe G1 Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis NasdaqGS:GTHX Opbrengsten, kosten en inkomsten (USD Millions ) Datum Inkomsten Inkomsten G+A Uitgaven R&D-uitgaven 30 Jun 24 58 -45 61 29 31 Mar 24 84 -31 65 35 31 Dec 23 83 -48 72 43 30 Sep 23 78 -71 80 52 30 Jun 23 89 -78 88 63 31 Mar 23 57 -126 96 72 31 Dec 22 51 -148 101 83 30 Sep 22 47 -154 101 86 30 Jun 22 28 -171 101 87 31 Mar 22 24 -171 100 85 31 Dec 21 31 -148 96 75 30 Sep 21 42 -134 98 72 30 Jun 21 64 -103 92 69 31 Mar 21 60 -95 81 68 31 Dec 20 45 -99 69 72 30 Sep 20 29 -109 57 81 30 Jun 20 2 -130 50 127 31 Mar 20 0 -130 44 109 31 Dec 19 0 -122 41 88 30 Sep 19 0 -111 35 135 30 Jun 19 0 -99 29 70 31 Mar 19 0 -89 23 53 31 Dec 18 0 -85 19 70 30 Sep 18 0 -78 14 0 30 Jun 18 0 -74 11 0 31 Mar 18 0 -68 9 17 31 Dec 17 0 -65 7 54 30 Sep 17 0 -60 6 0 30 Jun 17 0 -52 5 0 31 Mar 17 0 -45 4 0 31 Dec 16 0 -35 5 0 31 Dec 15 1 -22 3 0 31 Dec 14 1 -7 3 0
Kwaliteitswinsten: GTHX is momenteel verliesgevend.
Groeiende winstmarge: GTHX is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: GTHX is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 9.2% per jaar verminderd.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van GTHX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: GTHX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).
Rendement op eigen vermogen
Hoge ROE: GTHX heeft een negatief Return on Equity ( -182.05% ), omdat het momenteel verliesgevend is.
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
